News - Boehringer Ingelheim, Sandoz

Filter

Popular Filters

1 to 25 of 216 results

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

15-04-2014

German family-owned drug major Boehringer Ingelheim today posted financial results for 2013, noting that,…

Boehringer IngelheimFinancialPharmaceutical

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

EMA/CHMP recommends empagliflozin for approval for type 2 diabetes

23-03-2014

German family-owned drug major Boehringer Ingelheim and partner Eli Lilly of the USA have announce a…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

FDA issues CRL on empagliflozin, noting manufacturing deficiencies

05-03-2014

There was disappointment today for US drug major Eli Lilly and family-owned German pharma firm Boehringer…

Boehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaPharmaceuticalProductionRegulationUSA

New Ph III data show tiotropium Respimat effective across asthma severities

03-03-2014

German family-owned drug major Boehringer Ingelheim has released new data from large scale, Phase III…

Boehringer IngelheimPharmaceuticalResearchRespimatRespiratory and Pulmonarytiotropium

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

20-02-2014

US clinical-stage biotech firm Vitae Pharmaceuticals says it has earned a $14 million milestone payment…

BiotechnologyBoehringer IngelheimFinancialNeurologicalResearchVitae Pharmaceuticals

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

19-02-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG), in an early benefit assessment…

Boehringer IngelheimGermanyGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulation

“Differing views” see Zealand and Boehringer change collaboration compound

“Differing views” see Zealand and Boehringer change collaboration compound

20-01-2014

Zealand Pharma and Boehringer Ingelheim will change the development program involving novel glucagon/GLP-1…

Boehringer IngelheimDenmarkDiabetesGermanyPharmaceuticalResearchZealand Pharma

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

FORMA meets milestones under Boehringer Ingelheim cancer accord

FORMA meets milestones under Boehringer Ingelheim cancer accord

10-01-2014

US drug discovery company FORMA Therapeutics revealed that it has achieved several discovery milestones…

Boehringer IngelheimFORMA TherapeuticsLicensingOncologyPharmaceuticalResearch

Sandoz to commercialize Taiwan Liposome’s antifungal

Sandoz to commercialize Taiwan Liposome’s antifungal

19-12-2013

Taipei-based biopharmaceutical company Taiwan Liposome Company has entered into a collaboration agreement…

Amphotericin BAntibiotics and Infectious diseasesAsia-PacificGenericsLicensingNovartisSandozTaiwan Liposome

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

19-12-2013

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), has initiated a Phase III clinical…

AbbVieBiosimilarsHumiraImmunologicalsNorthern EuropeResearchSandoz

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

19-12-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has received Danish marketing authorization…

DenmarkPharmaceuticalRegulationRespiratory and PulmonarySandozVectura

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

17-12-2013

New data show that family-owned German drug major Boehringer Ingelheim’s second-generation protease…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalResearch

Apricus expands Vitaros deal with Novartis unit

Apricus expands Vitaros deal with Novartis unit

16-12-2013

USA-based Apricus Biosciences has expanded its exclusive license agreement with Hexal AG, an affiliate…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalSandozVitaros

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

03-12-2013

UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

Survey aims to discover how early diabetes diagnoses can aid better outcomes

Survey aims to discover how early diabetes diagnoses can aid better outcomes

02-12-2013

A multinational survey of more than 10,000 people with type 2 diabetes has been launched by German family-owned…

Boehringer IngelheimDiabetesEli LillyGlobalPharmaceuticalResearch

1 to 25 of 216 results

Back to top